Akcea, Ionis Close Licensing Agreement with Pfizer on New Drug

Date : 11/19/2019 @ 10:52PM
Source : Dow Jones News
Stock : Akcea Therapeutics Inc (AKCA)
Quote : 19.3  -0.19 (-0.97%) @ 4:59AM
After Hours
Last Trade
Last $ 19.30 ◊ 0.00 (0.00%)

Akcea, Ionis Close Licensing Agreement with Pfizer on New Drug

Akcea Therapeutics (NASDAQ:AKCA)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Akcea Therapeutics Charts.
   By Stephen Nakrosis 

Akcea Therapeutics Inc. (AKCA) and Ionis Pharmaceuticals Inc. (IONS) said Tuesday they closed an exclusive licensing deal with Pfizer Inc. (PFE) for AKCEA-ANGPTL3-L(Rx).

The companies said AKCEA-ANGPTL3-L(Rx) is an investigational therapy discovered by Ionis which is being developed for the treatment of certain cardiovascular and metabolic diseases.

Under the terms of the deal, Pfizer will receive an exclusive license to develop, make and commercialize AKCEA-ANGPTL3-L(Rx) worldwide.

Akcea and Ionis will receive $250 million upfront license fee, to be split equally. Akcea, which is a majority-owned affiliate of Ionis, will settle its $125 million obligation to Ionis in Akcea common stock, the companies said.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

November 19, 2019 17:37 ET (22:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AKCA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.